Preclinical research supported the development of targeted monoclonal antibodies—bemarituzumab, zolbetuximab, and ramucirumab—for advanced FGFR2b-, CLDN18.2-, and VEGFR2-positive G/GEJ adenocarcinomas. Here, KDR is linked to adenocarcinoma.